Pulmonary adenocarcinoma: A renewed entity in 2011

Respirology

Volumn 17, Issue 1, 2012, Pages 50-65

  Kadara, Humam ^a   Kabbout, Mohamed ^a   Wistuba, Ignacio I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

airway epithelium; field cancerization; genetics; lung cancer; molecular biology

Indexed keywords

B RAF KINASE; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INOSITOL; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; MYC PROTEIN; PROTEIN MDM2; SURVIVIN; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR SOX2; Y BOX BINDING PROTEIN 1;

BRONCHUS BIOPSY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER SURGERY; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CELL HETEROGENEITY; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 17P; CHROMOSOME 3P; CHROMOSOME DELETION; DISEASE MARKER; DNA METHYLATION; DNA MICROARRAY; ENZYME ACTIVATION; EPIGENETICS; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENOMICS; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG NON SMALL CELL CANCER; MOLECULAR PATHOLOGY; NONHUMAN; ORGANOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION;

ADENOCARCINOMA; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84255161043     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02095.x     Document Type: Review

References (145)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J. Clin. 2010; 61: 69-90.
2. Herbst RS, Heymach JV, Lippman SM,. Lung cancer. N. Engl. J. Med. 2008; 359: 1367-80.
3. Gold KA, Kim ES, Lee JJ, et al., The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev. Res. (Phila.) 2011; 4: 962-72.
4. Aberle DR, Adams AM, Berg CD, et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011; 365: 395-409.
5. Wistuba II, Gazdar AF,. Lung cancer preneoplasia. Annu. Rev. Pathol. 2006; 1: 331-48.
6. Wistuba II,. Genetics of preneoplasia: lessons from lung cancer. Curr. Mol. Med. 2007; 7: 3-14. (Pubitemid 46322275)
7. Yatabe Y, Borczuk AC, Powell CA,. Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer 2011; 74: 7-11.
8. Scagliotti G, Brodowicz T, Shepherd FA, et al., Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 2011; 6: 64-70.
9. Scagliotti GV, Parikh P, von Pawel J, et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008; 26: 3543-51.
10. Kabat GC, Wynder EL,. Lung cancer in nonsmokers. Cancer 1984; 53: 1214-21. (Pubitemid 14196507)
11. Khuder SA,. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001; 31: 139-48. (Pubitemid 32107010)
12. Rudin CM, Avila-Tang E, Harris CC, et al., Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin. Cancer Res. 2009; 15: 5646-61.
13. Sun S, Schiller JH, Gazdar AF,. Lung cancer in never smokers-a different disease. Nat. Rev. Cancer 2007; 7: 778-90. (Pubitemid 47463669)
14. Gazdar AF, Thun MJ,. Lung cancer, smoke exposure, and sex. J. Clin. Oncol. 2007; 25: 469-71. (Pubitemid 350002950)
15. Wakelee HA, Chang ET, Gomez SL, et al., Lung cancer incidence in never smokers. J. Clin. Oncol. 2007; 25: 472-8. (Pubitemid 350002951)
16. Le Calvez F, Mukeria A, Hunt JD, et al., TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005; 65: 5076-83. (Pubitemid 40827316)
17. Mounawar M, Mukeria A, Le Calvez F, et al., Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res. 2007; 67: 5667-72. (Pubitemid 46984998)
18. Pao W, Miller V, Zakowski M, et al., EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. U.S.A. 2004; 101: 13306-11. (Pubitemid 39209661)
19. Reynolds SH, Anna CK, Brown KC, et al., Activated protooncogenes in human lung tumors from smokers. Proc. Natl Acad. Sci. U.S.A. 1991; 88: 1085-9. (Pubitemid 21916169)
20. Ridanpaa M, Karjalainen A, Anttila S, et al., Genetic alterations in p53 and K-ras in lung-cancer in relation to histopathology of the tumor and smoking history of the patient. Int. J. Oncol. 1994; 5: 1109-17. (Pubitemid 24318742)
21. Rodenhuis S, Slebos RJ, Boot AJ, et al., Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988; 48: 5738-41.
22. Shigematsu H, Lin L, Takahashi T, et al., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 2005; 97: 339-46. (Pubitemid 40425952)
23. Tam IY, Chung LP, Suen WS, et al., Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res. 2006; 12: 1647-53.
24. Travis WD, Garg K, Franklin WA, et al., Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J. Thorac. Oncol. 2006; 1: S13-9. (Pubitemid 47181353)
25. Motoi N, Szoke J, Riely GJ, et al., Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am. J. Surg. Pathol. 2008; 32: 810-27.
26. Travis WD, Brambilla E, Noguchi M, et al., International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J. Thorac. Oncol. 2011; 6: 244-85.
27. Wistuba II, Behrens C, Milchgrub S, et al., Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18: 643-50. (Pubitemid 29080321)
28. Wistuba II, Behrens C, Virmani AK, et al., High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000; 60: 1949-60. (Pubitemid 30207657)
29. Wistuba II, Behrens C, Virmani AK, et al., Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 1999; 59: 1973-9. (Pubitemid 29186174)
30. Shigematsu H, Takahashi T, Nomura M, et al., Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005; 65: 1642-6. (Pubitemid 40478587)
31. Stephens P, Hunter C, Bignell G, et al., Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004; 431: 525-6.
32. Bass AJ, Watanabe H, Mermel CH, et al., SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 2009; 41: 1238-42.
33. Yuan P, Kadara H, Behrens C, et al., Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS ONE 2010; 5: e9112.
34. Kwei KA, Kim YH, Girard L, et al., Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008; 27: 3635-40. (Pubitemid 351793793)
35. Tanaka H, Yanagisawa K, Shinjo K, et al., Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007; 67: 6007-11. (Pubitemid 47037477)
36. Weir BA, Woo MS, Getz G, et al., Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-8. (Pubitemid 350231325)
37. Ding L, Getz G, Wheeler DA, et al., Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75.
38. Barbacid M,. Ras genes. Annu. Rev. Biochem. 1987; 56: 779-827.
39. Campbell SL, Khosravi-Far R, Rossman KL, et al., Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-413. (Pubitemid 28458409)
40. Harris TJ, McCormick F,. The molecular pathology of cancer. Nat. Rev. Clin. Oncol. 2010; 7: 251-65.
41. Brunner TB, Hahn SM, Gupta AK, et al., Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res. 2003; 63: 5656-68. (Pubitemid 37187458)
42. Hatzivassiliou G, Song K, Yen I, et al., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
43. Haura EB, Ricart AD, Larson TG, et al., A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2010; 16: 2450-7.
44. Yatabe Y,. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010; 29: 23-36.
45. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-39. (Pubitemid 38637993)
46. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. (Pubitemid 38720929)
47. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6. (Pubitemid 47206930)
48. Kwak EL, Bang YJ, Camidge DR, et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363: 1693-703.
49. Koivunen JP, Mermel C, Zejnullahu K, et al., EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008; 14: 4275-83.
50. Pao W, Girard N,. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12: 175-80.
51. Greulich H,. The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer 2010; 1: 1200-10.
52. Nigro JM, Baker SJ, Preisinger AC, et al., Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8. (Pubitemid 20001591)
53. Takahashi T, Nau MM, Chiba I, et al., p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-4. (Pubitemid 19273938)
54. Hayashi N, Sugimoto Y, Tsuchiya E, et al., Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun. 1994; 202: 1426-30.
55. Packenham JP, Taylor JA, White CM, et al., Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin. Cancer Res. 1995; 1: 687-90.
56. Merlo A, Herman JG, Mao L, et al., 5âCpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1995; 1: 686-92.
57. Sun Y, Ren Y, Fang Z, et al., Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J. Clin. Oncol. 2010; 28: 4616-20.
58. Pinkel D, Segraves R, Sudar D, et al., High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 1998; 20: 207-11. (Pubitemid 28455458)
59. Pollack JR, Perou CM, Alizadeh AA, et al., Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet. 1999; 23: 41-6. (Pubitemid 29418785)
60. Kim TM, Yim SH, Lee JS, et al., Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin. Cancer Res. 2005; 11: 8235-42.
61. Tonon G, Wong KK, Maulik G, et al., High-resolution genomic profiles of human lung cancer. Proc. Natl Acad. Sci. U.S.A. 2005; 102: 9625-30. (Pubitemid 40981731)
62. Balsara BR, Testa JR,. Chromosomal imbalances in human lung cancer. Oncogene 2002; 21: 6877-83. (Pubitemid 35221934)
63. Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, et al., DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 1998; 22: 79-82. (Pubitemid 28217810)
64. Luk C, Tsao MS, Bayani J, et al., Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet. Cytogenet. 2001; 125: 87-99. (Pubitemid 32448052)
65. Pei J, Balsara BR, Li W, et al., Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 2001; 31: 282-7. (Pubitemid 32521759)
66. Petersen I, Bujard M, Petersen S, et al., Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res. 1997; 57: 2331-5. (Pubitemid 27255883)
67. Massion PP, Kuo WL, Stokoe D, et al., Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 2002; 62: 3636-40. (Pubitemid 34728838)
68. Job B, Bernheim A, Beau-Faller M, et al., Genomic aberrations in lung adenocarcinoma in never smokers. PLoS ONE 2010; 5: e15145.
69. Soh J, Okumura N, Lockwood WW, et al., Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE 2009; 4: e7464.
70. Yuan S, Yu SL, Chen HY, et al., Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. J. Clin. Oncol. 2011; 29: 3435-42.
71. Bhattacharjee A, Richards WG, Staunton J, et al., Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. U.S.A. 2001; 98: 13790-5. (Pubitemid 33115977)
72. Garber ME, Troyanskaya OG, Schluens K, et al., Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. U.S.A. 2001; 98: 13784-9. (Pubitemid 33115976)
73. Hayes DN, Monti S, Parmigiani G, et al., Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 2006; 24: 5079-90. (Pubitemid 46631412)
74. Yatabe Y, Mitsudomi T, Takahashi T,. TTF-1 expression in pulmonary adenocarcinomas. Am. J. Surg. Pathol. 2002; 26: 767-73. (Pubitemid 34546942)
75. Westra WH,. Early glandular neoplasia of the lung. Respir. Res. 2000; 1: 163-9.
76. Chapman AD, Kerr KM,. The association between atypical adenomatous hyperplasia and primary lung cancer. Br. J. Cancer 2000; 83: 632-6. (Pubitemid 30636305)
77. Tang X, Shigematsu H, Bekele BN, et al., EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005; 65: 7568-72. (Pubitemid 41297226)
78. Tang X, Varella-Garcia M, Xavier AC, et al., Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev. Res. (Phila.) 2008; 1: 192-200.
79. Kitamura H, Kameda Y, Ito T, et al., Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am. J. Clin. Pathol. 1999; 111: 610-22. (Pubitemid 29200948)
80. Westra WH, Baas IO, Hruban RH, et al., K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996; 56: 2224-8. (Pubitemid 26119929)
81. Chiosea S, Jelezcova E, Chandran U, et al., Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007; 67: 2345-50. (Pubitemid 46424256)
82. Selamat SA, Galler JS, Joshi AD, et al., DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS ONE 2011; 6: e21443.
83. Yatabe Y, Kosaka T, Takahashi T, et al., EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am. J. Surg. Pathol. 2005; 29: 633-9. (Pubitemid 40577873)
84. Yoshida Y, Shibata T, Kokubu A, et al., Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005; 50: 1-8. (Pubitemid 41297463)
85. Slaughter DP, Southwick HW, Smejkal W,. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
86. Auerbach O, Stout AP, Hammond EC, et al., Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N. Engl. J. Med. 1961; 265: 253-67.
87. Sin DD, Man SF, McWilliams A, et al., Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am. J. Respir. Crit. Care Med. 2006; 173: 535-9.
88. Steiling K, Ryan J, Brody JS, et al., The field of tissue injury in the lung and airway. Cancer Prev. Res. (Phila.) 2008; 1: 396-403.
89. Wistuba II, Berry J, Behrens C, et al., Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin. Cancer Res. 2000; 6: 2604-10. (Pubitemid 30482094)
90. Nelson MA, Wymer J, Clements N, Jr., Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Lett. 1996; 103: 115-21. (Pubitemid 26125172)
91. Belinsky SA, Nikula KJ, Palmisano WA, et al., Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. U.S.A. 1998; 95: 11891-6.
92. Belinsky SA, Palmisano WA, Gilliland FD, et al., Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002; 62: 2370-7. (Pubitemid 34411720)
93. Mao L, Lee JS, Kurie JM, et al., Clonal genetic alterations in the lungs of current and former smokers. J. Natl Cancer Inst. 1997; 89: 857-62. (Pubitemid 27268450)
94. Wistuba II, Lam S, Behrens C, et al., Molecular damage in the bronchial epithelium of current and former smokers. J. Natl Cancer Inst. 1997; 89: 1366-73. (Pubitemid 27418028)
95. Powell CA, Klares S, O'Connor G, et al., Loss of heterozygosity in epithelial cells obtained by bronchial brushing: clinical utility in lung cancer. Clin. Cancer Res. 1999; 5: 2025-34. (Pubitemid 29399254)
96. Franklin WA, Gazdar AF, Haney J, et al., Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J. Clin. Invest. 1997; 100: 2133-7. (Pubitemid 27459370)
97. Zochbauer-Muller S, Lam S, Toyooka S, et al., Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int. J. Cancer 2003; 107: 612-6. (Pubitemid 37296123)
98. Soria JC, Rodriguez M, Liu DD, et al., Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. 2002; 62: 351-5. (Pubitemid 34106401)
99. Heller G, Zielinski CC, Zochbauer-Muller S,. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 2010; 29: 95-107.
100. Hackett NR, Heguy A, Harvey BG, et al., Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am. J. Respir. Cell Mol. Biol. 2003; 29: 331-43. (Pubitemid 37093991)
101. Spira A, Beane J, Shah V, et al., Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl Acad. Sci. U.S.A. 2004; 101: 10143-8. (Pubitemid 38891209)
102. Beane J, Sebastiani P, Liu G, et al., Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol. 2007; 8: R201.
103. Schembri F, Sridhar S, Perdomo C, et al., MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc. Natl Acad. Sci. U.S.A. 2009; 106: 2319-24.
104. Spira A, Beane JE, Shah V, et al., Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat. Med. 2007; 13: 361-6. (Pubitemid 46376687)
105. Gustafson AM, Soldi R, Anderlind C, et al., Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med. 2010; 2: 26ra5.
106. Sridhar S, Schembri F, Zeskind J, et al., Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics 2008; 9: 259.
107. Zhang X, Sebastiani P, Liu G, et al., Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol. Genomics 2010; 41: 1-8.
108. Boyle JO, Gumus ZH, Kacker A, et al., Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev. Res. (Phila.) 2010; 3: 266-78.
109. Garraway LA, Sellers WR,. Lineage dependency and lineage-survival oncogenes in human cancer. Nat. Rev. Cancer 2006; 6: 593-602. (Pubitemid 44140858)
110. Kantarjian H, Sawyers C, Hochhaus A, et al., Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002; 346: 645-52. (Pubitemid 34815868)
111. Demetri GD, von Mehren M, Blanke CD, et al., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347: 472-80. (Pubitemid 34879334)
112. Garraway LA, Widlund HR, Rubin MA, et al., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436: 117-22. (Pubitemid 40966196)
113. Cheung HW, Cowley GS, Weir BA, et al., Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl Acad. Sci. U.S.A. 2011; 108: 12372-7.
114. Minoo P, Su G, Drum H, et al., Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos. Dev. Biol. 1999; 209: 60-71. (Pubitemid 29194313)
115. Yuan B, Li C, Kimura S, et al., Inhibition of distal lung morphogenesis in Nkx2.1(-/-) embryos. Dev. Dyn. 2000; 217: 180-90. (Pubitemid 30080497)
116. Kimura S, Hara Y, Pineau T, et al., The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996; 10: 60-9. (Pubitemid 26025299)
117. Ikeda K, Clark JC, Shaw-White JR, et al., Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J. Biol. Chem. 1995; 270: 8108-14.
118. Kendall J, Liu Q, Bakleh A, et al., Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 16663-8. (Pubitemid 350211073)
119. Hsu DS, Acharya CR, Balakumaran BS, et al., Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc. Natl Acad. Sci. U.S.A. 2009; 106: 5312-7.
120. Winslow MM, Dayton TL, Verhaak RG, et al., Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011; 473: 101-4.
121. Barletta JA, Perner S, Iafrate AJ, et al., Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J. Cell. Mol. Med. 2009; 13: 1977-86.
122. Tang X, Kadara H, Behrens C, et al., Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin. Cancer Res. 2011; 17: 2434-43.
123. Barlesi F, Pinot D, Legoffic A, et al., Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br. J. Cancer 2005; 93: 450-2. (Pubitemid 43080019)
124. Berghmans T, Paesmans M, Mascaux C, et al., Thyroid transcription factor 1-a new prognostic factor in lung cancer: a meta-analysis. Ann. Oncol. 2006; 17: 1673-6. (Pubitemid 44680888)
125. Perner S, Wagner PL, Soltermann A, et al., TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J. Pathol. 2009; 217: 65-72.
126. Anagnostou VK, Syrigos KN, Bepler G, et al., Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J. Clin. Oncol. 2009; 27: 271-8.
127. Ishii Y, Rex M, Scotting PJ, et al., Region-specific expression of chicken Sox2 in the developing gut and lung epithelium: regulation by epithelial-mesenchymal interactions. Dev. Dyn. 1998; 213: 464-75. (Pubitemid 28546125)
128. Que J, Okubo T, Goldenring JR, et al., Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm. Development 2007; 134: 2521-31. (Pubitemid 47074146)
129. Gontan C, de Munck A, Vermeij M, et al., Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev. Biol. 2008; 317: 296-309.
130. Que J, Luo X, Schwartz RJ, et al., Multiple roles for Sox2 in the developing and adult mouse trachea. Development 2009; 136: 1899-907.
131. Whitsett JA, Haitchi HM, Maeda Y,. Intersections between pulmonary development and disease. Am. J. Respir. Crit. Care Med. 2011; 184: 401-6.
132. Boiani M, Scholer HR,. Regulatory networks in embryo-derived pluripotent stem cells. Nat. Rev. Mol. Cell Biol. 2005; 6: 872-84. (Pubitemid 41568736)
133. Boyer LA, Lee TI, Cole MF, et al., Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-56. (Pubitemid 41345211)
134. Hussenet T, Dali S, Exinger J, et al., SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS ONE 2010; 5: e8960.
135. Maier S, Wilbertz T, Braun M, et al., SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum. Pathol. 2011; 42: 1078-88.
136. Wilbertz T, Wagner P, Petersen K, et al., SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod. Pathol. 2011; 24: 944-53.
137. Sholl LM, Barletta JA, Yeap BY, et al., Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am. J. Surg. Pathol. 2010; 34: 1193-8.
138. Lu Y, Futtner C, Rock JR, et al., Evidence that SOX2 overexpression is oncogenic in the lung. PLoS ONE 2010; 5: e11022.
139. Xiang R, Liao D, Cheng T, et al., Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br. J. Cancer 2011; 104: 1410-7.
140. McCaughan F, Pole JC, Bankier AT, et al., Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am. J. Respir. Crit. Care Med. 2010; 182: 83-91.
141. Meyerson M, Gabriel S, Getz G,. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010; 11: 685-96.
142. Campbell PJ, Stephens PJ, Pleasance ED, et al., Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 2008; 40: 722-9. (Pubitemid 351748860)
143. Lee W, Jiang Z, Liu J, et al., The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-7.
144. Pleasance ED, Stephens PJ, O'Meara S, et al., A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 184-90.
145. Beane J, Vick J, Schembri F, et al., Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev. Res. (Phila.) 2011; 4: 803-17.